Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT00071838
Show Display Options
Rank Status Study
1 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab

Study has passed its completion date and status has not been verified in more than two years.